EA200301120A1 - Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена - Google Patents
Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаенаInfo
- Publication number
- EA200301120A1 EA200301120A1 EA200301120A EA200301120A EA200301120A1 EA 200301120 A1 EA200301120 A1 EA 200301120A1 EA 200301120 A EA200301120 A EA 200301120A EA 200301120 A EA200301120 A EA 200301120A EA 200301120 A1 EA200301120 A1 EA 200301120A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- citrate
- triazatetracyclo
- hexadeca
- relates
- pentaena
- Prior art date
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
Abstract
Данное изобретение относится к цитрату 5,8,14-триазатетрацикло-[10.3.1.0.0]гексадека-2(11),3,5,7,9-пентаена (формула 1) и его фармацевтическим композициям. Данное изобретение также относится к различным формам цитрата, особенно, его гидрату и его безводному/практически безводному полиморфу. Данное изобретение также относится к способу получения указанных форм цитрата.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29086301P | 2001-05-14 | 2001-05-14 | |
PCT/IB2002/001450 WO2002092597A1 (en) | 2001-05-14 | 2002-04-26 | The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200301120A1 true EA200301120A1 (ru) | 2004-02-26 |
EA005529B1 EA005529B1 (ru) | 2005-04-28 |
Family
ID=23117854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200301120A EA005529B1 (ru) | 2001-05-14 | 2002-04-26 | Цитрат 5,8,14-триазатетрацикло-(10.3.1.0.0)-гексадека-2(11),3,5,7,9-пентаена |
Country Status (37)
Country | Link |
---|---|
US (1) | US6787549B2 (ru) |
EP (1) | EP1390366B1 (ru) |
JP (1) | JP4137645B2 (ru) |
KR (1) | KR20040008175A (ru) |
CN (1) | CN1509288A (ru) |
AP (1) | AP1429A (ru) |
AR (1) | AR035889A1 (ru) |
AT (1) | ATE303386T1 (ru) |
BG (1) | BG108344A (ru) |
CA (1) | CA2446988A1 (ru) |
CZ (1) | CZ20032917A3 (ru) |
DE (1) | DE60205888T2 (ru) |
DO (1) | DOP2002000390A (ru) |
DZ (1) | DZ3503A1 (ru) |
EA (1) | EA005529B1 (ru) |
EE (1) | EE200300557A (ru) |
ES (1) | ES2245731T3 (ru) |
GT (1) | GT200200081A (ru) |
HR (1) | HRP20030911A2 (ru) |
HU (1) | HUP0304085A3 (ru) |
IL (1) | IL157874A0 (ru) |
IS (1) | IS6956A (ru) |
MA (1) | MA27021A1 (ru) |
MX (1) | MXPA03010365A (ru) |
MY (1) | MY134123A (ru) |
NO (1) | NO20035035L (ru) |
NZ (1) | NZ528209A (ru) |
OA (1) | OA12600A (ru) |
PA (1) | PA8545001A1 (ru) |
PE (1) | PE20021095A1 (ru) |
PL (1) | PL366774A1 (ru) |
SK (1) | SK13372003A3 (ru) |
TN (1) | TNSN03112A1 (ru) |
UA (1) | UA73421C2 (ru) |
UY (1) | UY27287A1 (ru) |
WO (1) | WO2002092597A1 (ru) |
ZA (1) | ZA200307234B (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9814592B1 (pt) * | 1997-12-31 | 2010-06-01 | composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento. | |
CN1596128A (zh) * | 2001-11-30 | 2005-03-16 | 辉瑞产品公司 | 5,7,14-三氮杂四环[10.3.1.0(2,11).0(4,9)]-十六碳-2(11)3,5,7,9-五烯的药物组合物 |
BRPI0410219A (pt) * | 2003-05-20 | 2006-05-09 | Pfizer Prod Inc | composições farmacêuticas de vareniclina |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
JP2010527907A (ja) * | 2006-11-09 | 2010-08-19 | ファイザー・プロダクツ・インク | ニコチン様中間体の多形体 |
WO2009109651A1 (en) * | 2008-03-06 | 2009-09-11 | Medichem, S.A. | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE |
US8039620B2 (en) | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
US8980873B2 (en) * | 2008-12-11 | 2015-03-17 | Cti Biopharma Corp. | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
US20100189790A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
US20120093887A1 (en) | 2009-06-10 | 2012-04-19 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
RU2012102052A (ru) | 2009-06-22 | 2013-11-20 | Тева Фармасьютикал Индастриз Лтд. | Твердые формы солей варениклина и способы их получения |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
CN104334561B (zh) | 2012-04-13 | 2016-06-22 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
EP3756653A1 (en) | 2019-06-28 | 2020-12-30 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Microparticulate varenicline citrate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9814592B1 (pt) * | 1997-12-31 | 2010-06-01 | composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento. | |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
-
2002
- 2002-04-26 EA EA200301120A patent/EA005529B1/ru not_active IP Right Cessation
- 2002-04-26 UA UA20031110265A patent/UA73421C2/uk unknown
- 2002-04-26 OA OA1200300290A patent/OA12600A/en unknown
- 2002-04-26 CN CNA028099117A patent/CN1509288A/zh active Pending
- 2002-04-26 CZ CZ20032917A patent/CZ20032917A3/cs unknown
- 2002-04-26 WO PCT/IB2002/001450 patent/WO2002092597A1/en active IP Right Grant
- 2002-04-26 DZ DZ023503A patent/DZ3503A1/fr active
- 2002-04-26 SK SK1337-2003A patent/SK13372003A3/sk unknown
- 2002-04-26 NZ NZ528209A patent/NZ528209A/en unknown
- 2002-04-26 IL IL15787402A patent/IL157874A0/xx unknown
- 2002-04-26 EE EEP200300557A patent/EE200300557A/xx unknown
- 2002-04-26 EP EP02724553A patent/EP1390366B1/en not_active Expired - Lifetime
- 2002-04-26 ES ES02724553T patent/ES2245731T3/es not_active Expired - Lifetime
- 2002-04-26 AT AT02724553T patent/ATE303386T1/de not_active IP Right Cessation
- 2002-04-26 DE DE60205888T patent/DE60205888T2/de not_active Expired - Fee Related
- 2002-04-26 MX MXPA03010365A patent/MXPA03010365A/es active IP Right Grant
- 2002-04-26 JP JP2002589481A patent/JP4137645B2/ja not_active Expired - Fee Related
- 2002-04-26 PL PL02366774A patent/PL366774A1/xx not_active Application Discontinuation
- 2002-04-26 HU HU0304085A patent/HUP0304085A3/hu unknown
- 2002-04-26 CA CA002446988A patent/CA2446988A1/en not_active Abandoned
- 2002-04-26 DO DO2002000390A patent/DOP2002000390A/es unknown
- 2002-04-26 KR KR10-2003-7014752A patent/KR20040008175A/ko not_active Application Discontinuation
- 2002-05-06 US US10/139,449 patent/US6787549B2/en not_active Expired - Fee Related
- 2002-05-09 GT GT200200081A patent/GT200200081A/es unknown
- 2002-05-09 AP APAP/P/2002/002522A patent/AP1429A/en active
- 2002-05-10 PE PE2002000392A patent/PE20021095A1/es not_active Application Discontinuation
- 2002-05-13 UY UY27287A patent/UY27287A1/es not_active Application Discontinuation
- 2002-05-13 MY MYPI20021725A patent/MY134123A/en unknown
- 2002-05-13 AR ARP020101735A patent/AR035889A1/es unknown
- 2002-05-14 PA PA20028545001A patent/PA8545001A1/es unknown
-
2003
- 2003-07-08 TN TNPCT/IB2002/001450A patent/TNSN03112A1/fr unknown
- 2003-09-15 IS IS6956A patent/IS6956A/is unknown
- 2003-09-16 ZA ZA200307234A patent/ZA200307234B/en unknown
- 2003-11-10 MA MA27390A patent/MA27021A1/fr unknown
- 2003-11-10 HR HR20030911A patent/HRP20030911A2/xx not_active Application Discontinuation
- 2003-11-11 BG BG108344A patent/BG108344A/bg unknown
- 2003-11-13 NO NO20035035A patent/NO20035035L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200301120A1 (ru) | Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена | |
EA200301121A1 (ru) | Тартраты 5,8,14-триазатетрацикло[10.3.1.02,11.04,9]гексадека-2(11),3,5,7,9-пентаена | |
EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
EA200400491A1 (ru) | Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции | |
EA200400606A1 (ru) | ИНГИБИТОРЫ ФАКТОРА Ха И ДРУГИХ СЕРИНОВЫХ ПРОТЕАЗ, ВОВЛЕЧЁННЫХ В КОАГУЛЯЦИОННЫЙ КАСКАД | |
EA200400387A1 (ru) | Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний | |
EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
PT1379520E (pt) | Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b | |
WO2006113552A8 (en) | Cyanoarylamines | |
BR9904998A (pt) | Derivados de hidroxamida do ácido 5-oxo-pirrolidina-2-carboxìlico | |
SG159380A1 (en) | Heteroaryl compounds useful as inhibitors of gsk-3 | |
EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
NO985518D0 (no) | Morfinanderivater og medisinsk anvendelse derav | |
EA200200774A1 (ru) | Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции | |
EA200000804A1 (ru) | Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина | |
EA200400140A1 (ru) | Пероральные противодиабетические агенты | |
DE69920923D1 (de) | Anthranilsäurederivate | |
EA200500899A1 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
EA200301203A1 (ru) | Новые соединения и композиции как ингибиторы катепсина | |
EA200400806A1 (ru) | Способ получения эхинокандиновых соединений | |
WO2004067703A3 (en) | 5ht7 antagonists and inverse agonists | |
DE60114640D1 (en) | Antithrombosemittel | |
EA200600563A1 (ru) | Способ получения рензаприда и его промежуточных соединений |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |